JP2024532288A5 - - Google Patents
Info
- Publication number
- JP2024532288A5 JP2024532288A5 JP2024512072A JP2024512072A JP2024532288A5 JP 2024532288 A5 JP2024532288 A5 JP 2024532288A5 JP 2024512072 A JP2024512072 A JP 2024512072A JP 2024512072 A JP2024512072 A JP 2024512072A JP 2024532288 A5 JP2024532288 A5 JP 2024532288A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- antipurine
- agonist
- regimen
- loading
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163236155P | 2021-08-23 | 2021-08-23 | |
| US63/236,155 | 2021-08-23 | ||
| PCT/US2022/041050 WO2023027994A1 (en) | 2021-08-23 | 2022-08-22 | Methods for treating nervous system disorders with antipurinergic agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024532288A JP2024532288A (ja) | 2024-09-05 |
| JP2024532288A5 true JP2024532288A5 (enExample) | 2025-09-29 |
Family
ID=85321996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024512072A Pending JP2024532288A (ja) | 2021-08-23 | 2022-08-22 | 抗プリン作動薬を用いて神経系障害を処置するための方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240277641A1 (enExample) |
| EP (1) | EP4366828A1 (enExample) |
| JP (1) | JP2024532288A (enExample) |
| CN (1) | CN118103072A (enExample) |
| AU (1) | AU2022332894A1 (enExample) |
| CA (1) | CA3227596A1 (enExample) |
| IL (1) | IL310559A (enExample) |
| WO (1) | WO2023027994A1 (enExample) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04009310A (es) * | 2002-03-26 | 2005-01-25 | Eastern Virginia Med School | Suramin y derivados del mismo como microbicidas y contraceptivos. |
| EP2770985A4 (en) * | 2011-10-25 | 2015-01-21 | U S Phytotherapy Inc | ARTEMISININE AND BERBERINE COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF |
| IL282156B (en) * | 2014-07-29 | 2022-07-01 | Shenzhen Hightide Biopharmaceutical Ltd | Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof |
| CN118697876A (zh) * | 2017-02-09 | 2024-09-27 | 完美日光有限公司 | 用于自闭症谱系障碍药物治疗的方法 |
| JP7749169B2 (ja) * | 2019-06-07 | 2025-10-06 | クヴァトリス セラピューティクス， インコーポレイテッド | 中枢神経系障害を処置するための組成物および方法 |
| IL302224A (en) * | 2020-10-22 | 2023-06-01 | Paxmedica Inc | Administration of anti-purinergic preparations for the treatment of disorders of the nervous system |
-
2022
- 2022-08-22 WO PCT/US2022/041050 patent/WO2023027994A1/en not_active Ceased
- 2022-08-22 JP JP2024512072A patent/JP2024532288A/ja active Pending
- 2022-08-22 IL IL310559A patent/IL310559A/en unknown
- 2022-08-22 CA CA3227596A patent/CA3227596A1/en active Pending
- 2022-08-22 EP EP22861939.1A patent/EP4366828A1/en not_active Withdrawn
- 2022-08-22 CN CN202280057126.5A patent/CN118103072A/zh active Pending
- 2022-08-22 AU AU2022332894A patent/AU2022332894A1/en active Pending
-
2024
- 2024-02-07 US US18/435,069 patent/US20240277641A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018329568B2 (en) | Combination therapy of lasmiditan and a CGRP antagonist for use in the treatment of migraine | |
| Ueno et al. | Role of platelets and antiplatelet therapy in cardiovascular disease | |
| RS62329B1 (sr) | Dozni oblici ruksolitiniba sa produženim vremenom oslobađanja | |
| JP2018528215A (ja) | ピプラドロールを用いる発達障害の治療方法 | |
| CN108135872A (zh) | 用于治疗认知缺陷的谷氨酰胺拮抗剂 | |
| US20150104511A1 (en) | Pharmaceutical Antiretroviral Combinations Comprising Lamivudine, Festinavir and Nevirapine | |
| KR20210100136A (ko) | C형 간염 바이러스를 치료하기 위한 고도의 활성 약물 조합물 | |
| AU2021261965A1 (en) | Regimens for treating hiv infections and aids | |
| US20110065754A1 (en) | Iminosugars and methods of treating filoviral diseases | |
| JP2024532288A5 (enExample) | ||
| US20100292217A1 (en) | Ranolazine for the treatment of cns disorders | |
| JP2023546923A5 (enExample) | ||
| JP2022549066A5 (enExample) | ||
| US20250345350A1 (en) | Treating pain associated with central sensitization | |
| IE80774B1 (en) | Nmda antagonists | |
| US20110053884A1 (en) | Potent combinations of zidovudine and drugs that select for the k65r mutation in the hiv polymerase | |
| SK168196A3 (en) | Anti-hiv triple combination | |
| CN119451676A (zh) | 神经障碍的治疗 | |
| US20240058328A1 (en) | Masitinib for the treatment of alzheimer's disease | |
| Tomitaka et al. | Regionally different effects of scopolamine on NMDA antagonist-induced heat shock protein HSP70 | |
| Ticku et al. | Membrane mechanisms of tremor | |
| Kaplan | Enteric-coated mycophenolate sodium (myfortic®): an overview of current and future use in transplantation | |
| Goel et al. | Efficacy and safety of lamotrigine in patients with trigeminal neuralgia: a comparison with carbamazepine. | |
| EP3758690B1 (en) | Pharmaceutical formulation for the use in the treatment of depressive and anxiety disorders | |
| Young | 3.6 Ketamin, S-Ketamin |